BCAB logo

BIOATLA INC

BCABNASDAQ
🏆 #5105 by market capEarnings Nov 11US Equity
$1.74▲ $0.42 (+31.44%)
Market closed · at close
🔔
Track BCAB
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 31.4%
7d▼ 3.1%
14d▼ 3.1%
30d▼ 3.1%
ytd▼ 93.9%
1y▼ 95.0%
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
-81.8%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
0.4x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.58 – $2.06
52-Week Range
$1.07 – $71.50
Volume (shares)
1,031,528
Avg Volume (shares)
—
Shares Outstanding
1.7M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$7M
P/E Ratio
—
P/S Ratio
0.4x
EPS (TTM)
$-25.56
Dividend Yield
—
Dilution (1yr)
−97.6%
BCAB logo

BIOATLA INC

BCAB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▼ −81.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-2053.7%▼ −2342.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$59M▼ −19.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$48M▼ −33.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.2M▼ −97.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$918K▼ −$47M YoY
StockOtter · stockotter.space

About BIOATLA INC

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy3
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.